

191D3
1E4
7B2
NC23
15H8
NC41
NC39
15B3
202A5
Numax Fab
OD 450 nm
1.2
0.8
0.4
0.0
10-6
10-7
10-8
10-9
10-10
10-11
[M]

Figure 1




7B2
RSV400
15H8
RSV404
NC41
RSV116
RSV407
OD 450 nm
2.0
1.5
1.0
0.5
0.0
10-11
10-10
10-9
10-8
10-7
10-6
[M]

Figure 2

Figure 3A


Long
OD450-620
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
1
µM





RSV-B-1
OD450-620
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
1
µM
7B2
RSV106
RSV400
15B3
RSV205
RSV402
RSV403
Synagis Mab

Figure 3B


Long
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-6
-5
-4
-3
-2
-1
0
1
µM


RSV-B-1
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
1
2
µM
15H8
RSV404
NC41
RSV116
RSV407
Numax Fab
Synagis



7B2 Long
7B2 R7C2/11
7B2 R7C2/1
7B2 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-5
10-6
10-7
10-8
10-9
[M]

Figure 4A



15H8 Long
15H8 R7C2/11
15H8 R7C2/1
15H8 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-9
10-8
10-7
10-6
10-5
[M]

Figure 4B



NC41 Long
NC41 R7C2/11
NC41 R7C2/1
NC41 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-9
10-8
10-7
10-6
10-5
[M]

Figure 4C



RSV400 Long
RSV400 R7C2/11
RSV400 R7C2/1
RSV400 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
[M]
10-7
10-8
10-9
10-10
10-11

Figure 4D



RSV404 Long
RSV404 R7C2/11
RSV404 R7C2/1
RSV404 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-11
10-10
10-9
10-8
10-7
[M]

Figure 4E



RSV407 Long
RSV407 R7C2/11
RSV407 R7C2/1
RSV407 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-11
10-10
10-9
10-8
10-7
[M]

Figure 4F



RSV403 Long
RSV403 R7C2/11
RSV403 R7C2/1
RSV403 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-7
10-8
10-9
10-10
10-11
[M]

Figure 4G

Figure 5



Long
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-6
-5
-4
-3
-2
-1
0
1
µM
B-1
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
µM
NC41
RSV408
RSV409
RSV407
RSV410
Synagis

Figure 6

	V5L	A14P	S19R	I20L	E44G	G54D	A74S	G78L	A83R	D85E	R105Q	Q108L	# mutations
NC41v01	I	p	r	l	g	.	.	l	.	e	q	l	9
NC41v02	I	p	r	.	g	.	s	l	.	e	q	l	9
NC41v03	I	p	r	.	g	.	s	l	r	e	q	l	10
NC41v04	I	p	.	.	g	.	s	l	r	.	q	l	8
NC41v05	I	p	.	.	g	.	s	l	.	e	q	l	8
NC41v06	I	p	r	l	g	d	.	l	r	e	q	l	11
NC41v07	I	p	.	.	g	.	.	l	.	.	q	l	6
NC41v08	I	p	.	.	g	.	.	.	r	e	q	l	7
NC41v09	I	p	.	.	g	.	s	.	r	.	q	l	7
NC41v10	I	p	.	.	g	.	.	.	.	.	q	l	5
NC41v11	I	.	.	.	g	.	.	.	.	.	q	l	4
NC41v12	I	p	.	.	.	.	.	.	.	.	q	l	4
NC41v13	I	p	r	l	g	.	.	.	.	e	q	l	8
NC41v14	I	p	r	l	g	.	s	l	.	e	q	l	10
NC41v15	I	.	r	l	g	.	.	l	.	e	q	l	8
NC41v16	I	p	r	l	.	.	.	l	.	e	q	l	8
NC41v17	I	p	r	l	g	.	s	l	r	e	q	l	11
NC41v18	I	p	r	l	g	d	s	l	r	e	q	l	12

Figure 7

	FR1	CDR1	FR2	CDR2
NC41	evqlvesgggglvqaggslsiscaasggsls	NYVLG	wfrqapgkerefva	AINWRGDITIGPPNVEG
NC41v01	evqllesgggglvq**p**ggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v02	evqllesgggglvq**p**ggslr**i**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v03	evqllesgggglvq**p**ggslr**i**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v04	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v05	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v06	evqllesgggglvq**p**ggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWR**D**DITIGPPNVEG
NC41v07	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v08	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v09	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v10	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v11	evqllesgggglvqaggslsiscaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v12	evqllesgggglvq**p**ggslsiscaasggsls	NYVLG	wfrqapgkerefva	AINWRGDITIGPPNVEG
NC41v13	evqllesgggglvq**p**ggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v14	evqllesgggglvq**p**ggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v15	evqllesgggglvqaggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v17	evqllesgggglvq**p**ggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWRGDITIGPPNVEG
NC41v18	evqllesgggglvq**p**ggslr**l**scaasggsls	NYVLG	wfrqapgk**g**refva	AINWR**D**DITIGPPNVEG

Figure 7: Continued

	FR3	CDR3	FR4
NC41	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgrgtqvtvss
NC41v01	rftisrdnakntlylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v02	rftisrdnsknt**l**ylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v03	rftisrdnsknt**l**ylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v04	rftisrdnsknt**l**ylqmnsl**r**pddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v05	rftisrdn**s**knt**l**ylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v06	rftisrdnakntlylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v07	rftisrdnakntlylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v08	rftisrdnakntlylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v09	rftisrdnsknt**l**ylqmnsl**r**pddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v10	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v11	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v12	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v13	rftisrdnakntgylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v14	rftisrdn**s**knt**l**ylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v15	rftisrdnakntlylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v17	rftisrdn**s**knt**l**ylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v18	rftisrdn**s**knt**l**ylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss

Figure 8A




RSV-Long
OD450-620
0.8
0.7
0.6
0.5
0.4
0.3
0.2
10-6 10-5 10-4 10-3 10-2 10-1 100 101
µM
RSV-B-1
OD450-620
0.7
0.6
0.5
0.4
0.3
0.2
10-5 10-4 10-3 10-2 10-1 100 101
µM
1A4
1A4v3
1A4v6
1A4v18
RSV407
RSV414
RSV426
Synagis

Figure 8B


Long
% Viral antigen
1.0
0.8
0.6
0.4
0.2
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
µM
B-1
OD450-620
0.7
0.6
0.5
0.4
0.3
0.2
0.1
10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
µM
RSV407
RSV414
RSV426
RSV427
Synagis



RSV407
RSV434
Long (A strain)
OD450-620nm
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.0001
0.001
0.01
0.1
1
10
100
[NB] in nM

Figure 9A



B strain
RSV407
RSV434
OD450-620nm
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.0001
0.001
0.01
0.1
1
10
100
[NB] in nM

Figure 9B



Lung lavage virus titers
Log10 PFU/g lung
0
1
2
3
4
5
6
PBS
5mg/ml
1mg/ml
0.2mg/ml
0.04mg/ml
*
*
*
TREATMENT

Figure 10A



Lung lavage q-RT-PCR
FOLD REDUCTION IN MEAN C_T VALUES
90
80
70
60
50
40
30
20
10
0
5mg/ml
1mg/ml
0.2mg/ml
0.04mg/ml
TREATMENT
*
*
*
*

Figure 10B



MEAN (±SD) VIRUS TITER (log10 PFU/g lung)
0
1
2
3
4
5
6
0
1
3.9
20.8
TREATMENT (mean mg/kg)
* P<0.05 v Untreated
*
*
*
*

Figure 11A



MEAN (±SD) VIRUS TITER (log10 PFU/g lung)
0
1
2
3
4
5
6
0
1
3.9
20.8
TREATMENT (mean mg/kg)
* P<0.05 v Untreated
*
*
*
*

Figure 11B